Baker Brothers Advisors - Q1 2021 holdings

$23.1 Billion is the total value of Baker Brothers Advisors's 126 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 19.0% .

 Value Shares↓ Weighting
SGEN BuySeagen Inc.$6,564,018,000
-20.7%
47,270,759
+0.0%
28.46%
-8.8%
BGNE  BeiGene, Ltd.sponsored adr$4,061,710,000
+34.7%
11,668,8970.0%17.61%
+55.0%
INCY BuyIncyte Corporation$2,600,753,000
-6.6%
32,001,387
+0.0%
11.28%
+7.5%
KOD  Kodiak Sciences Inc.$1,573,848,000
-22.8%
13,879,9520.0%6.82%
-11.2%
ACAD BuyACADIA Pharmaceuticals Inc.$1,081,296,000
-51.7%
41,910,704
+0.0%
4.69%
-44.5%
ALXN SellAlexion Pharmaceuticals, Inc.$610,617,000
-55.4%
3,993,312
-54.4%
2.65%
-48.7%
NVTA BuyInvitae Corporation$601,776,000
-8.0%
15,749,182
+0.6%
2.61%
+5.8%
BMRN  BioMarin Pharmaceutical Inc.$573,068,000
-13.9%
7,589,2940.0%2.48%
-0.9%
ASND  Ascendis Pharma A/Ssponsored adr$456,270,000
-22.7%
3,540,2700.0%1.98%
-11.1%
PRLD BuyPrelude Therapeutics Incorporated$438,665,000
-39.4%
10,123,824
+0.1%
1.90%
-30.3%
ABCL  AbCellera Biologics Inc.$354,888,000
-15.6%
10,450,1800.0%1.54%
-2.8%
ARGX Buyargenx SEsponsored adr$308,315,000
+2.8%
1,119,557
+9.8%
1.34%
+18.3%
IGMS BuyIGM Biosciences, Inc.$242,041,000
-12.8%
3,156,102
+0.4%
1.05%
+0.3%
MRTX  Mirati Therapeutics, Inc.$241,496,000
-22.0%
1,409,7840.0%1.05%
-10.3%
MDGL  Madrigal Pharmaceuticals, Inc.$175,363,000
+5.2%
1,499,2130.0%0.76%
+21.0%
AMRN SellAmarin Corporation plcsponsored adr$164,276,000
+20.0%
26,453,422
-5.5%
0.71%
+38.0%
GBT BuyGlobal Blood Therapeutics, Inc.$131,111,000
+228.9%
3,217,441
+249.6%
0.57%
+278.7%
BCRX BuyBioCryst Pharmaceuticals, Inc.$129,269,000
+36.7%
12,710,818
+0.1%
0.56%
+57.3%
IMCR NewImmunocore Holdings plcads$107,307,0002,520,730
+100.0%
0.46%
PACB  Pacific Biosciences of California, Inc.$106,658,000
+28.4%
3,201,9720.0%0.46%
+47.6%
TIL NewInstil Bio, Inc.$97,654,0003,893,700
+100.0%
0.42%
TLIS NewTalis Biomedical Corporation$97,337,0007,574,835
+100.0%
0.42%
HRTX  Heron Therapeutics, Inc.$97,174,000
-23.4%
5,994,7040.0%0.42%
-11.9%
CERS  Cerus Corporation$82,416,000
-13.2%
13,713,1950.0%0.36%
-0.3%
ALLK SellAllakos Inc.$80,696,000
-19.3%
703,050
-1.6%
0.35%
-7.2%
DBVT  DBV Technologies S.A.sponsored adr$77,894,000
+103.4%
14,614,2640.0%0.34%
+134.7%
NRIX BuyNurix Therapeutics, Inc.$76,297,000
+29.7%
2,454,082
+37.2%
0.33%
+49.1%
KYMR  Kymera Therapeutics, Inc.$76,135,000
-37.3%
1,959,2110.0%0.33%
-27.9%
RYTM BuyRhythm Pharmaceuticals, Inc.$74,017,000
+7.6%
3,479,873
+50.3%
0.32%
+23.9%
INSM  Insmed Incorporated$73,433,000
+2.3%
2,156,0010.0%0.32%
+17.8%
APLS BuyApellis Pharmaceuticals, Inc.$71,832,000
+40.1%
1,674,004
+86.7%
0.31%
+61.1%
NBIX  Neurocrine Biosciences, Inc.$65,836,000
+1.5%
676,9750.0%0.28%
+16.8%
KRYS BuyKrystal Biotech, Inc.$58,582,000
+39.7%
760,412
+8.8%
0.25%
+60.8%
FMTX  Forma Therapeutics Holdings, Inc.$56,737,000
-19.7%
2,024,8760.0%0.25%
-7.5%
HZNP  Horizon Therapeutics Public Ltd Co$55,142,000
+25.8%
599,1100.0%0.24%
+44.8%
BCEL  Atreca, Inc.$54,157,000
-5.1%
3,532,7600.0%0.24%
+9.3%
ZYME  Zymeworks Inc.$53,954,000
-33.2%
1,708,4720.0%0.23%
-23.0%
ADAP  Adaptimmune Therapeutics plcsponsored adr$52,202,000
-1.5%
9,830,8770.0%0.23%
+13.0%
KNSA  Kiniksa Pharmaceuticals, Ltd.$51,820,000
+4.8%
2,799,5770.0%0.22%
+21.0%
RARE  Ultragenyx Pharmaceutical Inc.$50,604,000
-17.7%
444,4440.0%0.22%
-5.6%
NLTX  Neoleukin Therapeutics, Inc.$47,046,000
-12.7%
3,821,7400.0%0.20%
+0.5%
IMTX BuyImmatics N.V.$44,759,000
+129.8%
3,992,756
+121.2%
0.19%
+165.8%
ACHL NewAchilles Therapeutics plcsponsored ads$42,887,0002,591,366
+100.0%
0.19%
DSGN NewDesign Therapeutics, Inc.$42,955,0001,436,636
+100.0%
0.19%
MRUS  Merus N.V.$42,563,000
+19.2%
2,037,4690.0%0.18%
+37.0%
VSTM BuyVerastem, Inc.$42,038,000
+94.6%
17,019,294
+67.8%
0.18%
+124.7%
BCAB  BioAtla, Inc.$41,943,000
+49.5%
825,0000.0%0.18%
+71.7%
ALT BuyAltimmune, Inc.$38,978,000
+83.4%
2,758,518
+46.4%
0.17%
+111.2%
FLGT SellFulgent Genetics, Inc.$38,746,000
+50.1%
401,016
-19.1%
0.17%
+73.2%
PTGX  Protagonist Therapeutics, Inc.$37,197,000
+28.5%
1,436,1920.0%0.16%
+47.7%
ALGS  Aligos Therapeutics, Inc.$36,611,000
-17.8%
1,610,0000.0%0.16%
-5.4%
AXSM SellAxsome Therapeutics, Inc.$35,581,000
-43.9%
628,414
-19.3%
0.15%
-35.6%
ADCT  ADC Therapeutics SA$34,616,000
-23.7%
1,418,1070.0%0.15%
-12.3%
CCXI  ChemoCentryx, Inc.$33,650,000
-17.2%
656,7100.0%0.15%
-4.6%
OPT  Opthea Limitedsponsored ads$31,664,000
-14.7%
3,308,7050.0%0.14%
-2.1%
AGLE  Aeglea BioTherapeutics, Inc.$27,008,000
+0.6%
3,410,1060.0%0.12%
+15.8%
NVAX SellNovavax, Inc.$26,064,000
+37.7%
143,756
-15.3%
0.11%
+59.2%
ALKS SellAlkermes plc$22,942,000
-25.1%
1,228,170
-20.0%
0.10%
-13.9%
MREO BuyMereo BioPharma Group plcads$22,646,000
+4.9%
6,719,948
+11.4%
0.10%
+21.0%
RETA  Reata Pharmaceuticals, Inc.cl a$22,330,000
-19.4%
223,9760.0%0.10%
-6.7%
OTIC NewOtonomy, Inc.$18,411,0007,220,074
+100.0%
0.08%
AUPH  Aurinia Pharmaceuticals Inc.$18,310,000
-6.1%
1,410,0640.0%0.08%
+8.2%
EWTX NewEdgewise Therapeutics, Inc.$16,250,000500,000
+100.0%
0.07%
XNCR  Xencor, Inc.$15,905,000
-1.3%
369,3700.0%0.07%
+13.1%
 Invitae Corporationnote 2.0% 9/1/2024$15,557,000
-5.4%
10,300,0000.0%0.07%
+8.1%
 BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024$15,299,000
-4.6%
15,000,0000.0%0.07%
+10.0%
ATHA  Athira Pharma, Inc.$14,837,000
-46.3%
806,3670.0%0.06%
-38.5%
ALBO  Albireo Pharma, Inc.$14,539,000
-6.0%
412,4660.0%0.06%
+8.6%
XENE BuyXenon Pharmaceuticals Inc.$13,454,000
+27.3%
751,639
+9.3%
0.06%
+45.0%
MIRM  Mirum Pharmaceuticals, Inc.$12,830,000
+13.5%
647,3130.0%0.06%
+30.2%
NewSarepta Therapeutics, Inc.dbcv 1.5% 11/15/2024$11,970,0009,174,000
+100.0%
0.05%
KDNY  Chinook Therapeutics, Inc.$11,635,000
-2.0%
748,6930.0%0.05%
+11.1%
SBTX  Silverback Therapeutics, Inc.$10,388,000
-5.8%
238,0950.0%0.04%
+7.1%
RVMD NewRevolution Medicines, Inc.$10,196,000222,222
+100.0%
0.04%
CBAY SellCymabay Therapeutics, Inc.$9,854,000
-40.7%
2,170,464
-25.0%
0.04%
-31.7%
GTH  Genetron Holdings Limitedads$9,771,000
+53.3%
455,3060.0%0.04%
+75.0%
HOOK  HOOKIPA Pharma Inc.$9,421,000
+21.3%
700,4810.0%0.04%
+41.4%
CRNX  Crinetics Pharmaceuticals, Inc.$9,420,000
+8.3%
616,5200.0%0.04%
+24.2%
ANAB  AnaptysBio, Inc.$9,206,000
+0.2%
427,1790.0%0.04%
+14.3%
ISEE  IVERIC bio, Inc.$8,689,000
-10.6%
1,406,0370.0%0.04%
+2.7%
NGM BuyNGM Biopharmaceuticals, Inc.$8,483,000
+162.6%
291,801
+173.7%
0.04%
+208.3%
GMDA SellGamida Cell Ltd.$8,391,000
-35.4%
1,037,226
-33.0%
0.04%
-26.5%
KRTX  Karuna Therapeutics, Inc.$8,412,000
+18.3%
69,9660.0%0.04%
+33.3%
ASMB  Assembly Biosciences, Inc.$7,091,000
-24.0%
1,541,4180.0%0.03%
-11.4%
CABA  Cabaletta Bio, Inc.$7,064,000
-11.1%
636,3630.0%0.03%
+3.3%
BLUE  bluebird bio, Inc.$6,844,000
-30.3%
226,9880.0%0.03%
-18.9%
MGNX  MacroGenics, Inc.$6,392,000
+39.3%
200,6790.0%0.03%
+64.7%
BNR  Burning Rock Biotech Limitedsponsored ads$5,630,000
+16.5%
209,1310.0%0.02%
+33.3%
NEXI NewNexImmune, Inc.$5,612,000294,117
+100.0%
0.02%
ORTX BuyOrchard Therapeutics plcads$5,332,000
+271.3%
734,431
+120.9%
0.02%
+360.0%
SGMO SellSangamo Therapeutics, Inc.$5,376,000
-59.8%
429,063
-50.0%
0.02%
-54.0%
SYRS  Syros Pharmaceuticals, Inc.$5,162,000
-31.1%
690,1670.0%0.02%
-21.4%
ITOS  Iteos Therapeutics, Inc.$5,139,000
+1.1%
150,3460.0%0.02%
+15.8%
DNLI  Denali Therapeutics Inc.$5,067,000
-31.8%
88,7380.0%0.02%
-21.4%
ALEC  Alector, Inc.$4,818,000
+33.1%
239,2280.0%0.02%
+50.0%
EVFM BuyEvofem Biosciences, Inc.$4,720,000
+376.3%
2,697,110
+555.6%
0.02%
+400.0%
REPL  Replimune Group, Inc.$4,684,000
-20.0%
153,5120.0%0.02%
-9.1%
TVTX NewTravere Therapeutics, Inc.$4,667,000186,915
+100.0%
0.02%
SRPT NewSarepta Therapeutics, Inc.$4,375,00058,700
+100.0%
0.02%
PASG  Passage Bio, Inc.$4,114,000
-31.6%
235,3620.0%0.02%
-21.7%
HRMY SellHarmony Biosciences Holdings, Inc.$4,084,000
-37.2%
123,600
-31.3%
0.02%
-28.0%
TCDA BuyTricida, Inc.$3,858,000
-13.0%
729,300
+15.9%
0.02%0.0%
TCRR BuyTCR2 Therapeutics Inc.$3,896,000
+13.6%
176,461
+59.1%
0.02%
+30.8%
AKRO  Akero Therapeutics, Inc.$3,434,000
+12.4%
118,3780.0%0.02%
+25.0%
LEGN  Legend Biotech Corporationsponsored ads$3,355,000
+3.0%
115,6260.0%0.02%
+25.0%
LOGC  LogicBio Therapeutics, Inc.$3,287,000
-4.6%
451,4780.0%0.01%
+7.7%
TARA  Protara Therapeutics, Inc.$3,143,000
-35.0%
199,6710.0%0.01%
-22.2%
XLRN  Acceleron Pharma Inc.$3,042,000
+6.0%
22,4300.0%0.01%
+18.2%
CNST  Constellation Pharmaceuticals, Inc.$2,684,000
-18.8%
114,7350.0%0.01%0.0%
IDRA SellIdera Pharmaceuticals, Inc.$2,661,000
-84.3%
2,047,180
-55.6%
0.01%
-81.2%
AUTL SellAutolus Therapeutics plcsponsored ads$2,646,000
-62.2%
461,726
-41.0%
0.01%
-57.7%
VKTX  Viking Therapeutics, Inc.$2,302,000
+12.3%
363,9800.0%0.01%
+25.0%
CHMA  Chiasma, Inc.$2,323,000
-28.0%
742,1330.0%0.01%
-16.7%
INZY  Inozyme Pharma, Inc.$2,119,000
-4.0%
106,9990.0%0.01%
+12.5%
MTEM  Molecular Templates, Inc.$1,689,000
+34.4%
133,8330.0%0.01%
+40.0%
AFMD  Affimed N.V.$1,302,000
+35.9%
164,6050.0%0.01%
+50.0%
LPTX  Leap Therapeutics, Inc.$1,063,000
-15.6%
559,7050.0%0.01%0.0%
OYST  Oyster Point Pharma, Inc.$1,123,000
-2.9%
61,4240.0%0.01%
+25.0%
 Bellicum Pharmaceuticals, Inc.$937,000
+6.6%
249,1230.0%0.00%
+33.3%
KZR  Kezar Life Sciences, Inc.$832,000
+14.1%
139,6760.0%0.00%
+33.3%
GLPG  Galapagos NVsponsored adr$862,000
-22.1%
11,1800.0%0.00%0.0%
ADMS  Adamas Pharmaceuticals, Inc.$710,000
+10.8%
147,9960.0%0.00%
+50.0%
GLMD  Galmed Pharmaceuticals Ltd.$634,000
+10.3%
184,9270.0%0.00%
+50.0%
FREQ SellFrequency Therapeutics, Inc.$528,000
-98.3%
55,555
-93.5%
0.00%
-98.2%
IFRX SellInflarx N.V.$538,000
-87.5%
138,040
-83.9%
0.00%
-87.5%
GNFT  Genfit SAads$68,000
-4.2%
14,7200.0%0.00%
SNSS ExitSunesis Pharmaceuticals, Inc.$0-53,066
-100.0%
0.00%
QURE ExituniQure N.V.$0-6,740
-100.0%
-0.00%
INFI ExitInfinity Pharmaceuticals, Inc.$0-522,360
-100.0%
-0.00%
RCUS ExitArcus Biosciences, Inc.$0-72,709
-100.0%
-0.01%
DRNA ExitDicerna Pharmaceuticals, Inc.$0-102,121
-100.0%
-0.01%
OVID ExitOvid Therapeutics Inc.$0-955,690
-100.0%
-0.01%
GOSS ExitGossamer Bio, Inc.$0-480,729
-100.0%
-0.02%
NTLA ExitIntellia Therapeutics, Inc.$0-111,296
-100.0%
-0.02%
VXRT ExitVaxart, Inc.$0-1,398,795
-100.0%
-0.03%
FPRX ExitFive Prime Therapeutics, Inc.$0-668,000
-100.0%
-0.04%
GWPH ExitGW Pharmaceuticals plcads$0-112,897
-100.0%
-0.05%
ADPT ExitAdaptive Biotechnologies Corporation$0-379,682
-100.0%
-0.08%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-05-17
Signatures

The EDGAR filing(s) were signed by:

About Baker Brothers Advisors

Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.

Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.

The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.

Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Incyte Corporation42Q3 202337.6%
ACADIA Pharmaceuticals Inc.42Q3 202310.9%
Biomarin Pharmaceuticals Inc.42Q3 20235.9%
BioCryst Pharmaceuticals, Inc.42Q3 20231.7%
Cerus Corporation42Q3 20230.9%
Insmed Incorporated42Q3 20230.4%
Mirati Therapeutics, Inc.41Q3 20231.8%
Bluebird Bio Inc.41Q3 20230.3%
Heron Therapeutics, Inc.39Q3 20231.5%
ChemoCentryx, Inc.37Q3 20220.6%

View Baker Brothers Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Baker Brothers Advisors Q1 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Neoleukin Therapeutics, Inc.August 17, 20239,469,83820.0%
Mereo Biopharma Group plcAugust 10, 202314,604,3912.2%
Verastem, Inc.August 10, 2023? ?
TScan Therapeutics, Inc.June 02, 20232,793,9386.5%
ACADIA PHARMACEUTICALS INCMay 24, 202343,084,28026.5%
INCYTE CORPMarch 15, 202336,280,96716.3%
Seagen Inc.March 13, 202346,985,65625.1%
Talis Biomedical CorpMarch 10, 202337,569,14066.2%
Aeglea BioTherapeutics, Inc.February 14, 20236,384,0139.9%
Merus N.V.February 14, 2023? ?

View Baker Brothers Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-03-25
SC 13D/A2024-03-25
42024-03-14
32024-03-07
42024-03-07
SC 13D2024-03-05
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Baker Brothers Advisors's complete filings history.

Compare quarters

Export Baker Brothers Advisors's holdings